Murphy Capital Management Inc Gilead Sciences, Inc. Transaction History

Murphy Capital Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$56.65 - $64.55 $204,733 - $233,283	-3,614 Closed	0 $0
Q3 2020 Oct 20, 2020	BUY	$62.1 - $78.08 $62,348 - $78,392	1,004 Added 38.47%	3,614 $228,000
Q2 2020 Aug 03, 2020	BUY	$72.34 - $84.0 $188,807 - $219,240	2,610 New	2,610 $200,000
Q2 2019 Jul 22, 2019	SELL	$61.87 - $69.38 $221,803 - $248,727	-3,585 Closed	0 $0
Q1 2019 Apr 11, 2019	SELL	$62.53 - $70.05 $90,668 - $101,572	-1,450 Reduced 28.8%	3,585 $233,000
Q4 2018 Feb 04, 2019	SELL	$60.54 - $79.0 $33,297 - $43,450	-550 Reduced 9.85%	5,035 $314,000
Q3 2018 Oct 10, 2018	SELL	$71.28 - $78.92 $21,384 - $23,676	-300 Reduced 5.1%	5,585 $431,000
Q2 2018 Jul 26, 2018	SELL	$64.88 - $75.68 $47,038 - $54,868	-725 Reduced 10.97%	5,885 $416,000
Q1 2018 Apr 17, 2018	SELL	$72.84 - $88.8 $43,266 - $52,747	-594 Reduced 8.25%	6,610 $498,000
Q4 2017 Jan 29, 2018	SELL	$71.15 - $83.52 $104,946 - $123,192	-1,475 Reduced 17.0%	7,204 $516,000
Q3 2017 Oct 19, 2017	BUY	$72.11 - $85.47 $625,842 - $741,794	8,679	8,679 $703,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Murphy Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Murphy Capital Management Inc with notifications on news.